National Pharmaceutical Office

National Pharmaceutical Office, commonly identified by its French name Office National Pharmaceutique and the abbreviation ONAPHA, was a state-owned pharmaceutical manufacturing enterprise in Burundi. Established in 1980 under the Ministry of Health, it was created to manufacture essential medicines for the Burundian market and to support pharmaceutical supply in neighboring countries. Its role reflected a broader public-sector strategy of building domestic industrial capacity in sectors considered important to health security and national economic development. The enterprise was initially associated with the Ministry of Health and was later transferred to the Ministry of Commerce and Finance. During the 1980s, ONAPHA operated within a wider group of Burundian public companies that the government sought to rehabilitate and place under more performance-oriented management. In 1988, the government service responsible for public enterprises was preparing a rehabilitation program for ONAPHA and other state companies, including CADEBU, OTRACO, OTRABU, and Verundi. The program was intended to provide a basis for performance contracts between the state and the enterprises. ONAPHA operated in an increasingly competitive environment as many prices were deregulated and state-owned companies were expected to compete with private businesses. By 1992, the company was manufacturing approximately 48 pharmaceutical products and supplied around one-quarter of the medicines used in Burundi. The Ministry of Health was its largest customer, purchasing products worth approximately 200 million Burundian francs, equivalent at the time to about 67 percent of the ministry's medicine budget. These figures indicate that ONAPHA was a significant supplier within the national health system, even though its manufacturing capabilities were constrained. The company faced operational difficulties, including outdated production equipment, cramped premises, and low utilization of its installed capacity. In 1992, it was reportedly operating at about 60 percent of capacity. Packaging materials such as bottles and metal cans had to be imported by air, increasing logistical complexity and production costs. These constraints weakened the company's ability to operate efficiently and contributed to government efforts to identify a buyer or otherwise restructure the enterprise. ONAPHA was privatized in 2005. The State Privatisation Agency, identified in French as the Service chargé des entreprises publiques, organized the privatization process and described it as transparent. The later ownership transition was not fully settled in the available historical account. As of March 2012, the Burundian government was negotiating with Société industrielle pharmaceutique du Burundi, or SIPHAR, a pharmaceutical group of Indian origin, to complete the sale of ONAPHA. The available references do not establish whether that transaction was completed, what the final ownership structure became, or whether the ONAPHA manufacturing operation continued under the same name. The brand's historical significance lies less in consumer marketing than in its role as a public health and industrial institution. It represented an attempt by Burundi to manufacture essential medicines domestically, reduce dependence on imports, and supply government health services. Its later privatization illustrates the transition of Burundian state enterprises toward private ownership and market-based operation, while its reported equipment, capacity, and packaging problems show the infrastructure challenges faced by pharmaceutical manufacturing in the country.

National Pharmaceutical Office, or Office National Pharmaceutique (ONAPHA), was established in Burundi in 1980 as a public enterprise under the Ministry of Health. Its mandate was to manufacture essential medicines for the national market and potentially export pharmaceutical products to neighboring countries. The enterprise formed part of Burundi's effort to develop domestic industrial capacity in a strategically important sector and to strengthen the supply of medicines to the public health system. The company was subsequently transferred from the Ministry of Health to the Ministry of Commerce and Finance. In the 1980s, ONAPHA was managed within a broader state-enterprise system. In 1988, the government service responsible for public enterprises was preparing a rehabilitation program for ONAPHA and several other state companies. The proposed program was intended to underpin performance contracts and improve the commercial and operational performance of public enterprises at a time when many prices had been deregulated and state-owned businesses were increasingly expected to compete with private firms. By 1992, ONAPHA reportedly manufactured about 48 products and supplied approximately 25 percent of the medicines used in Burundi. The Ministry of Health was the company's largest customer, spending approximately 200 million Burundian francs on ONAPHA products, or about 67 percent of its medicine budget. Despite this important role, the enterprise had significant structural weaknesses. Its equipment was outdated, its premises were cramped, and it was operating at only about 60 percent of capacity. Packaging materials, including bottles and metal cans, had to be imported by air, adding to the company's logistical burden. The government was seeking a buyer for ONAPHA as it considered ways to address these difficulties. The enterprise was privatized in 2005, with the State Privatisation Agency organizing the process. The available account describes the privatization as transparent but does not name the successful purchaser or provide transaction terms. In March 2012, the government was still negotiating with Société industrielle pharmaceutique du Burundi, known as SIPHAR and described as a group of Indian origin, to complete the sale of ONAPHA. The available sources do not establish whether the transaction was finalized or whether production continued under the ONAPHA name. ONAPHA's historical importance derives from its role as a national pharmaceutical manufacturer rather than from a consumer brand presence. It supplied a large share of medicines used by Burundi's health system and embodied the policy objective of producing essential drugs locally. Its history also illustrates the challenges of maintaining pharmaceutical manufacturing in a resource-constrained environment, including obsolete equipment, limited facilities, dependence on imported packaging, and the difficulty of transitioning a public enterprise to commercially sustainable ownership.

• 2012

  Negotiations with SIPHAR

  [1]National Pharmaceutical Officeen.wikipedia.org

  As of March 2012, the government is negotiating with Société industrielle pharmaceutique du Burundi to complete the sale of ONAPHA.

• 2005

  Privatization

  [1]National Pharmaceutical Officeen.wikipedia.org

  ONAPHA is privatized through a process organized by Burundi's State Privatisation Agency.

• 1992

  Peak documented role in Burundi's medicine supply

  [1]National Pharmaceutical Officeen.wikipedia.org

  ONAPHA is reported to manufacture about 48 products and supply roughly one-quarter of medicines used in Burundi, while the Ministry of Health remains its largest customer.

• 1988

  Public-enterprise rehabilitation planning

  [1]National Pharmaceutical Officeen.wikipedia.org

  The government service responsible for public enterprises prepares a rehabilitation program covering ONAPHA and other state companies, with performance contracts envisioned as a management framework.

• 1980

  ONAPHA is established

  [1]National Pharmaceutical Officeen.wikipedia.org

  Burundi establishes the National Pharmaceutical Office under the Ministry of Health as a public enterprise to manufacture essential medicines for the domestic market and neighboring countries.

A public-sector pharmaceutical manufacturer focused on essential medicines, domestic supply, and potential regional exports rather than a consumer-facing commercial brand.

• Pharmaceuticals · 1980

  Essential medicines

  ONAPHA's core output was a range of essential medicines intended for Burundi's health system and the wider local market. The available historical account does not identify individual formulations or therapeutic classes, but reports that the enterprise manufactured approximately 48 products by 1992.

• 2012

  Negotiated sale to SIPHARM&A

  Background

  Following the 2005 privatization process, the government was still working toward a completed transfer of the pharmaceutical enterprise.

  Action taken

  As of March 2012, Burundi was negotiating with Société industrielle pharmaceutique du Burundi, a group of Indian origin, over completion of ONAPHA's sale.

  Aftermath

  The available reference does not confirm whether the negotiations concluded or whether ONAPHA continued operating under its historical name.

  Source

• 2005

  Privatization of ONAPHAM&A

  Background

  The government sought a new ownership and operating structure for a public pharmaceutical manufacturer facing equipment, facilities, capacity-utilization, and input-supply constraints.

  Action taken

  Burundi's State Privatisation Agency organized the privatization of ONAPHA and described the process as transparent.

  Aftermath

  The available source does not identify the final buyer or transaction value. By March 2012, the government was negotiating with SIPHAR to complete the sale.

  Source

1. 1National Pharmaceutical Officeen.wikipedia.org